Lung Cancer 2008: Traditional and Novel Approaches

BREATHE LA recommends that you attend "Lung Cancer 2008: Traditional and Novel Approaches" in the Insights Into Cancer Seriies sponsored by Simms/Mann UCLA Center for Intergrative Oncology:

Lung cancer is a very common malignancy. Treatments are currently available for patients with all stages of disease, and much research is also being conducted to improve on currently available therapies. This talk discusses currently available therapies, including surgery, chemotherapy and radiation therapy. The role of surgical treatment and non-surgical interventional procedures for early and late stage lung cancer are covered. Agents targeting blood vessel formation and growth signals in cancer cells have recently entered clinical practice. These advances are discussed, as well as clinical trials available at UCLA applying these types of approaches.  Clinical trials often provide opportunities for patients to advance the science of lung cancer and to participate in trials of medications at an early stage of development.

Edward Garon, MD, is the Co-Director of Medical Oncology Program in Thoracic Malignancies, Assistant Professor of Medicine, Division of Hematology/Oncology, at the David Geffen School of Medicine at UCLA. Dr. Garon has published both laboratory and clinical research. Dr. Garon focuses on translating developments in the laboratory into clinical studies, and eventually clinical practice. He is conducting several clinical studies.  He actively sees patients with lung cancer, thus he understands the importance of quickly moving new therapies from research to bedside.

Jay M. Lee, MD, is the Surgical Director of the UCLA Thoracic Oncology Program and an Assistant Professor of Surgery, Division of Cardiothoracic Surgery, at the David Geffen School of Medicine at UCLA.  He has published both laboratory and clinical based research.  Dr. Lee is an investigator in the UCLA Lung Cancer Research Program and leads an immunotherapy trial.  His research effort is focused on translating investigator initiated discoveries from the laboratory into clinical studies.  He actively sees patients with lung cancer at early and late stages, provides surgical and interventional care for complete removal of the lung tumor, and performs procedures for palliative care to improve symptoms.